Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine

NCT05127486 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05127486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05127486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Completed
Start date
December 6, 2021
Completion date
May 23, 2023
Enrollment
580 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

episodic migraine, migraine